A novel, highly selective oral sphingosine 1-phosphate (S1P)–receptor modulator confirmed promise as a therapy for atopic dermatitis (AD) in a 12-week segment 2b trial, in…
A novel, highly selective oral sphingosine 1-phosphate (S1P)–receptor modulator confirmed promise as a therapy for atopic dermatitis (AD) in a 12-week segment 2b trial, in…